Skip to main content

Table 1 The clinical characteristics and laboratory findings of 42 patients treated with or without anti-MRSA drugs in this study

From: Clinical impact of methicillin-resistant staphylococcus aureus on bacterial pneumonia: cultivation and 16S ribosomal RNA gene analysis of bronchoalveolar lavage fluid

Clinical variates Group A Group B P-value
Treated with anti-MRSA drugs Treated without anti-MRSA drugs
(n = 13) (n = 29)
Age ± SD (years) 74.8 ± 10.1 74.6 ± 17.5 0.764
Male: Female 10:3 19:10 0.458
Underlying diseases**    
 None 2 (15.4 %) 4 (13.8 %) 0.898
 Malignancies 1 (7.7 %) 11 (37.9 %) 0.016
 Cerebrovascular disorders 5 (38.5 %) 10 (34.5 %) 0.813
 Chronic pulmonary diseases 4 (30.8 %) 5 (17.2 %) 0.382
 COPD 2 (15.4 %) 2 (6.9 %) 0.469
 Bronchiectasis/NTM 1 (7.7 %) 5 (17.2 %) 0.370
 Interstitial lung diseases 1 (7.7 %) 1 (3.4 %) 0.621
 Diabetes mellitus 4 (30.8 %) 3 (10.3 %) 0.178
 Dementia 4 (30.8 %) 6 (20.7 %) 0.519
 Heart diseases 4 (30.8 %) 5 (17.2 %) 0.382
 Hepatic diseases 1 (7.7 %) 1 (3.4 %) 0.621
 Renal diseases 1 (7.7 %) 4 (13.8 %) 0.550
 Hematology/Collagen-vascular diseases 1 (7.7 %) 4 (13.8 %) 0.550
ECOG performance status 3-4 75.0 % (9/12) 60.0 % (15/25) 0.371
Use of Glucocorticoid**/Immunosuppresant 1 (7.7 %) 5 (17.2 %) 0.37
Use of gastric tube 1 (7.7 %) 2 (6.9 %) 0.931
Histories/Risks of aspiration 8 (61.5 %) 15 (51.7 %) 0.568
Antibiotic therapy in the preceding 90 days 5 (38.5 %) 7 (24.1 %) 0.387
History of MRSA detection in the preceding 90 days 4 (30.8 %) 5 (17.2 %) 0.382
Type of pneumonia    
 CAP 0 (0.0 %) 2 (6.9 %) 0.161
 HCAP 2 (15.4 %) 15 (51.7 %) 0.015
 HAP 11 (84.6 %) 12 (41.3 %) 0.099
Radiologic findings of Chest CT*    
 Consolidation 7 (63.6 %) 12 (41.4 %) 0.474
 Bronchopneumonia 1 (9.1 %) 9 (31.0 %)) 0.052
 Complicated with cavitation/abscess formation 0 (0.0 %) 0 (0.0 %)
 Complicated with atelectasis 0 (0.0 %) 3 (10.3 %) 0.083
 Centrilobular nodules (DPB-like) 0 (0.0 %) 0 (0.0 %)
 Diffuse alveolar shadow (ARDS-like) 2 (18.2 %) 0 (0.0 %) 0.165
 Bronchiectasis 1 (9.1 %) 6 (20.7 %) 0.239
 Parapneumonic pleural effusion 5 (45.5 %) 3 (10.3 %) 0.082
  1. SD standard deviation, COPD chronic obstractive pulmonary disease, NTM nontuberculous mycobacterial infection, MRSA methicillin-resistant Staphylococcus aureus, ECOG Eastern Cooperative Oncology Group, CAP community-acquired pneumonia, HCAP helathcare-associated pneumonia, HAP hospital-acquired pneumonia, CT computed tomography, DPB diffuse pulmonary bronchiolitis, ARDS acute respiratory distress syndrome
  2. *includes diplicates, **corresponds to prednisolone 5 mg daily or greater